Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

Starbucks Corporation

organization80% conf.·synced Aug 13, 2026

Coffee company and coffeehouse chain

56
sourced metrics
256
relationships
20
stated objectives
1
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Eps
2.60USD
Aug 4, 2026source
Same Store Sales Growth
7.9percent
Aug 4, 2026source
Transaction Growth
4.2percent
Aug 4, 2026source
Forward Pe
35ratio
Jul 28, 2026source
Stock Price
23percent_ytd_change
Jul 28, 2026source
Dividend Per Share
0.62USD
May 29, 2026source
Principal Tendered
2598857000USD
May 15, 2026source
Options Open Interest
5800contracts
May 13, 2026source
Options Volume
692contracts
May 13, 2026source
Debt
5000000000USD
May 4, 2026source
Adjusted Eps
0.50USD
Apr 29, 2026source
Comparable Store Sales Growth
6.2percent
Apr 29, 2026source
International Comps Growth
2.6percent
Apr 29, 2026source
North America Comps Growth
7.1percent
Apr 29, 2026source
North America Average Ticket Growth
2.6percent
Apr 29, 2026source
Cash
91.8USD
Apr 29, 2026source
Store Count
41000stores
Apr 29, 2026source
Shares Outstanding
1.14billion_shares
Apr 29, 2026source

Stated objectives

U.S. comparable store sales growth target for FY2026

source
target: +3% or better stated

Global net new stores target for FY2026

source
target: 600-650 stores stated

U.S. company-operated net new stores target for FY2026

source
target: 150-175 stores stated

International net new stores target for FY2026, with China approximately half

source
target: 450-500 stores stated

Earnings per share guidance range for FY2026

source
target: $2.15-$2.40 stated

Operating margin target for FY2026 showing slight year-over-year growth

source
target: slight YoY growth stated

Cost reduction target over next 2-3 years focusing on G&A, procurement, and technology efficiency

source
target: $2 billion stated

Target number of coffeehouse uplifts to complete by end of 2026

source
target: 1,000+ stated

Consolidated revenue growth expected to be similar to comparable store sales growth for FY2026

source
target: similar to comp growth stated

Brand reinvigoration efforts

source
stated

Relationship graph · 256 connections

Employs
38
Competes with
32
Covered by
26
Developed by
21
financed by
16
located in
15
headquartered in
14
Supplies to
13

Via News coverage

Starbucks Bets on Tech and Steel to Engineer a Comeback: Inside the Multi-Year Turnaround
February 19, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com